Form 8-K

8-K — Phreesia, Inc.

Accession: 0001412408-26-000074

Filed: 2026-03-30

Period: 2026-03-30

CIK: 0001412408

SIC: 7389 (SERVICES-BUSINESS SERVICES, NEC)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — phr-20260330.htm (Primary)

EX-99.1 (phr-ex991q4fy26.htm)

EX-99.2 (phr-ex992q4fy26stakehold.htm)

GRAPHIC (phr-ex992q4fy26stakehold001.jpg)

GRAPHIC (phr-ex992q4fy26stakehold002.jpg)

GRAPHIC (phr-ex992q4fy26stakehold003.jpg)

GRAPHIC (phr-ex992q4fy26stakehold004.jpg)

GRAPHIC (phr-ex992q4fy26stakehold005.jpg)

GRAPHIC (phr-ex992q4fy26stakehold006.jpg)

GRAPHIC (phr-ex992q4fy26stakehold007.jpg)

GRAPHIC (phr-ex992q4fy26stakehold008.jpg)

GRAPHIC (phr-ex992q4fy26stakehold009.jpg)

GRAPHIC (phr-ex992q4fy26stakehold010.jpg)

GRAPHIC (phr-ex992q4fy26stakehold011.jpg)

GRAPHIC (phr-ex992q4fy26stakehold012.jpg)

GRAPHIC (phr-ex992q4fy26stakehold013.jpg)

GRAPHIC (phr-ex992q4fy26stakehold014.jpg)

GRAPHIC (phr-ex992q4fy26stakehold015.jpg)

GRAPHIC (phr-ex992q4fy26stakehold016.jpg)

GRAPHIC (phr-ex992q4fy26stakehold017.jpg)

GRAPHIC (phr-ex992q4fy26stakehold018.jpg)

GRAPHIC (phr-ex992q4fy26stakehold019.jpg)

GRAPHIC (phr-ex992q4fy26stakehold020.jpg)

GRAPHIC (phr-ex992q4fy26stakehold021.jpg)

GRAPHIC (phr-ex992q4fy26stakehold022.jpg)

GRAPHIC (phr-ex992q4fy26stakehold023.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: phr-20260330.htm · Sequence: 1

phr-20260330

false000141240800014124082026-03-302026-03-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported)

March 30, 2026

___________________________________

Phreesia, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware

(State or other jurisdiction of incorporation or organization)

001-38977

(Commission File Number)

20-2275479

(I.R.S. Employer Identification Number)

1521 Concord Pike, Suite 301 PMB 221

Wilmington, Delaware 19803

(Address of principal executive offices and zip code)

(888) 654-7473

(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, par value $0.01 per share PHR The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 - Results of Operations and Financial Condition

On March 30, 2026, Phreesia, Inc. (the “Company”) announced its financial results for the fiscal fourth quarter and fiscal year ended January 31, 2026 by issuing a stakeholder letter (the "Letter") and a press release. Copies of the press release and the Letter are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

The information furnished under this Item 2.02 and in the accompanying Exhibit 99.1 and Exhibit 99.2 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits.

Exhibit Number Description

99.1

Press release, dated March 30, 2026, by Phreesia, Inc.

99.2

Stakeholder letter, dated March 30, 2026, by Phreesia, Inc.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 30, 2026 Phreesia, Inc.

By: /s/ Balaji Gandhi

Name: Balaji Gandhi

Title: Chief Financial Officer

EX-99.1

EX-99.1

Filename: phr-ex991q4fy26.htm · Sequence: 2

Document

Exhibit 99.1

Phreesia Announces Fourth Quarter Fiscal 2026 Results

ALL-REMOTE COMPANY/WILMINGTON, Del. – March 30, 2026 – Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2026.

"We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal year 2026," said CEO and Co-Founder Chaim Indig.

Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2026 Stakeholder Letter.

Fiscal Fourth Quarter Ended January 31, 2026 Highlights

•Total revenue was $127.1 million in the quarter, up 16% year-over-year.

•Average number of healthcare services clients ("AHSCs") was 4,658 in the quarter, up 7% year-over-year.

•Total revenue per AHSC was $27,279 in the quarter, up 8% year-over-year. See "Key Metrics" below for additional information.

•Net income was $1.3 million in the quarter, as compared to net loss of $6.4 million in the same period in the prior year.

•Adjusted EBITDA1 was $29.4 million in the quarter, as compared to $16.4 million in the same period in the prior year.

•Net cash provided by operating activities was $33.7 million in the quarter, as compared to $16.3 million in the same period in the prior year.

•Free cash flow2 was $28.5 million in the quarter, as compared to $9.2 million in the same period in the prior year.

•Cash, cash equivalents and restricted cash as of January 31, 2026 was $73.8 million, down $32.5 million from October 31, 2025.

Fiscal Year Ended January 31, 2026 Highlights

•Total revenue was $480.6 million in fiscal 2026, up 14% year-over-year.

•AHSCs were 4,514 in fiscal 2026, up 7% year-over-year.

•Total revenue per AHSC was $106,467 in fiscal 2026, up 7% year-over-year. See "Key Metrics" below for additional information.

•Net income was $2.3 million in fiscal 2026, as compared to net loss of $58.5 million in fiscal year 2025.

•Adjusted EBITDA1 was $101.5 million in fiscal 2026, as compared to $36.8 million in fiscal 2025.

•Net cash provided by operating activities was $78.8 million in fiscal 2026, as compared to $32.4 million in fiscal 2025.

•Free cash flow2 was $54.4 million in fiscal 2026, as compared to $8.3 million in fiscal 2025.

•Cash, cash equivalents and restricted cash as of January 31, 2026 was $73.8 million, down from $84.2 million as of January 31, 2025.

1 Adjusted EBITDA is a non-GAAP measure. We calculate Adjusted EBITDA as net income or loss before interest expense, interest income, income tax (benefit) expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other income, net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. See “Non-GAAP Financial Measures” for more information and a reconciliation of Adjusted EBITDA to the closest GAAP measure.

2 Free cash flow is a non-GAAP measure. We calculate free cash flow as net cash (used in) provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. See the "Non-GAAP Financial Measures" section for a reconciliation of free cash flow to the closest GAAP measure.

AccessOne Acquisition

On November 12, 2025 (the “Closing Date”), we completed the acquisition (the “AccessOne Acquisition”) of AccessOne Parent Holdings, Inc. and its subsidiaries (collectively, “AccessOne”) for consideration transferred of approximately $164 million, including post-closing adjustments. The AccessOne Acquisition expands our addressable market for healthcare payments. Our payment solutions now offer healthcare providers a trusted, scalable, compliant and operationally efficient healthcare payment card that accelerates cash flow.

The purchase price was funded with a combination of cash and the net proceeds from a new, 364-day $110 million secured term loan (the “Bridge Loan”) entered into on the Closing Date.

Also on the Closing Date, we entered into an amendment (the “Credit Facility Amendment”) to our senior ABL facility with Capital One, National Association (as amended, the “Existing Capital One Credit Facility”). The Credit Facility Amendment amended the covenant limiting acquisitions to permit the acquisition of AccessOne, amended the covenant limiting additional indebtedness to accommodate the Bridge Loan, and amended the security interest supporting the Existing Capital One Credit Facility to permit the security interests granted in connection with the Bridge Loan. The amendment included further changes to sections governing mandatory and voluntary prepayments, negative covenants and events of default to accommodate the existence of the Bridge Loan.

For more information regarding the AccessOne Acquisition, the Bridge Loan and the Credit Facility Amendment, please see our Current Reports on Form 8-K filed with the SEC on September 4, 2025 and November 12, 2025.

New Capital One Credit Facility and Refinancing

On March 13, 2026, subsequent to the end of the fiscal year, we completed a refinancing pursuant to which we repaid all outstanding indebtedness and obligations under the Bridge Loan with $92 million of borrowings from a new 5-year, $275 million senior secured revolving credit facility (the "New Capital One Credit Facility") maturing on March 13, 2031. The New Capital One Credit Facility also replaces the Existing Capital One Credit Facility, which had no outstanding borrowings and was terminated on the same date. The unused borrowing capacity on New Capital One Credit Facility is available to the Company for working capital, capital expenditures, permitted acquisitions and general corporate purposes.

For more information regarding the New Capital One Credit Facility and the termination of the Bridge Loan and the Existing Capital One Credit Facility, please see our Current Report on Form 8-K filed with the SEC on March 16, 2026.

Fiscal 2027 Outlook

We are lowering our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million from a previous range of $545 million to $559 million. As we discussed on our last earnings call in December 2025, we are experiencing shorter visibility into spending commitments by certain pharmaceutical manufacturers. As we enter fiscal 2027, network solutions clients are committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December. Certain clients are committing fewer dollars due to brand-specific dynamics including the impact of regulatory policies. Though we do not believe these developments are signaling a structural shift in demand for Phreesia's solutions, there is now more variability in our internal network solutions revenue forecasting, particularly in the second half of each fiscal year. Our visibility into revenue across the other parts of our business is generally consistent with our views in December 2025. The revenue range provided for fiscal 2027 assumes approximately $37 million of contribution from AccessOne and no additional revenue from potential future acquisitions completed between now and January 31, 2027.

We are maintaining our Adjusted EBITDA outlook for fiscal 2027. We expect Adjusted EBITDA to be in the range of $125 million to $135 million. Our Adjusted EBITDA outlook implies that we will absorb much of the reduction in our revenue outlook. In addition to our continued confidence in the operating leverage embedded in our model, we have more recently identified significant opportunities to reduce our reliance on manual processes across Phreesia through the adoption of artificial intelligence. Initially, we expect to see efficiencies in our utilization of outsourced

resources. We continue to expect improvement in operating leverage across the Company through a focus on efficiency.

We are maintaining our expectation for AHSC growth in the mid-single-digit percentage range, and we are lowering our outlook for total revenue per AHSC to the low-single-digit percentage range for fiscal 2027, compared to low double-digit growth previously.

We believe our cash and cash equivalents and cash generated in our normal operations will be sufficient to reach our fiscal 2027 outlook and meet our obligations. As of January 31, 2026 we had $90 million outstanding under the Bridge Loan and no borrowings outstanding under the Existing Capital One Credit Facility.

Non-GAAP3 Financial Measures

We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other income, net and income tax (benefit) expense, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For further information regarding the non-GAAP financial measures included in this press release, including a reconciliation of GAAP to non-GAAP financial measures and an explanation of these measures, please see “Non-GAAP Financial Measures” below.

Available Information

We intend to use our Company website (including our Investor Relations website) as well as our Facebook, X, LinkedIn and Instagram accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, Adjusted EBITDA and cash flows; our expectations regarding demand for our solutions and visibility into future revenue; our expectations regarding improvement in operating leverage across the Company through a focus on efficiency; the expected results of the AccessOne Acquisition discussed herein, including anticipated additional revenue, Adjusted EBITDA and AHSCs; our ability to finance our plans to achieve our fiscal 2027 outlook with our current cash balance and cash generated in the normal course of business; and our outlook for fiscal 2027, including our expectations regarding revenue, Adjusted EBITDA, AHSCs and Total revenue per AHSC; and our growth strategies for the AccessOne business, our ability to offer the AccessOne solution to additional clients and our plans to augment our access to capital. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the ability to integrate operations or realize any operational or corporate synergies and other benefits from the AccessOne Acquisition; the competitive environment in which we operate; our ability to comply with the covenants in the New Capital One Credit Facility; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and

3 GAAP is defined as generally accepted accounting principles in the United States.

addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; and difficulties in integrating our acquisitions and investments; artificial intelligence that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data, increasing our regulatory and compliance burden and increasing competition; and other general, market, political, economic and business conditions (including from the results of the U.S. federal government, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above.

Conference Call Information

We will hold a conference call on Monday, March 30, 2026, at 5:00 p.m. Eastern Time to review our 2026 fiscal fourth quarter and fiscal 2026 financial results. To participate in our live conference call and webcast, please dial (800) 715-9871 (or (646) 307-1963 for international participants) using conference code number 7404611 or visit the “Events & Presentations” section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Phreesia

Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 180 million patient visits in 2025—1 in 6 visits across the U.S. This scale allows Phreesia to make meaningful impact across the healthcare ecosystem. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives operational efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

Investor Relations Contact:

Balaji Gandhi

Phreesia, Inc.

investors@phreesia.com

(929) 506-4950

Media Contact:

Nicole Gist

Phreesia, Inc.

nicole.gist@phreesia.com

(407) 760-6274

Phreesia, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share data)

January 31, 2026 January 31, 2025

(Unaudited)

Assets

Current:

Cash, cash equivalents, and restricted cash (including restricted cash of $1,691) $ 73,830  $ 84,220

Settlement assets 32,999  29,176

Accounts receivable, net of allowance for doubtful accounts of $1,523 and $1,468 as of January 31, 2026 and 2025, respectively 97,453  73,617

Cardholder receivables

38,330  —

Deferred purchase price receivables

18,003  —

Accrued interest and fees receivables

840  —

Deferred contract acquisition costs 410  401

Prepaid expenses and other current assets 17,978  15,871

Total current assets 279,843  203,285

Property and equipment, net of accumulated depreciation and amortization of $94,193 and $84,505 as of January 31, 2026 and 2025, respectively 20,332  23,651

Capitalized internal-use software, net of accumulated amortization of $69,390 and $55,991 as of January 31, 2026 and 2025, respectively 54,270  52,763

Operating lease right-of-use assets 2,002  1,477

Deferred contract acquisition costs 338  583

Intangible assets, net of accumulated amortization of $13,489 and $8,407 as of January 31, 2026 and 2025, respectively 79,761  28,143

Goodwill 170,064  75,845

Deferred tax assets

1,593  —

Other assets 2,442  2,668

Long-term cardholder receivables

47,723  —

Long-term deferred purchase price receivables

5,422  —

Total Assets $ 663,790  $ 388,415

Liabilities and Stockholders’ Equity

Current:

Settlement obligations $ 32,999  $ 29,176

Current portion of debt and finance lease liabilities 7,971  8,043

Current portion of operating lease liabilities 1,254  964

Accounts payable 11,477  5,622

Accrued expenses 41,257  37,460

Due to healthcare providers

38,056  —

Deferred revenue 49,522  32,758

Other current liabilities 705  —

Total current liabilities 183,241  114,023

Long-term debt and finance lease liabilities 92,117  8,150

Operating lease liabilities, non-current 1,107  646

Long-term due to healthcare providers

45,329  —

Long-term deferred revenue 244  119

Long-term deferred tax liabilities 4,498  484

Other long-term liabilities 47  185

Total Liabilities 326,583  123,607

Commitments and contingencies

Stockholders’ Equity:

Preferred stock, undesignated, $0.01 par value—20,000,000 shares authorized as of both January 31, 2026 and 2025; no shares issued or outstanding as of January 31, 2026 and 2025, respectively —  —

Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2026 and 2025; 62,020,186 and 60,083,444 shares issued as of January 31, 2026 and 2025, respectively 620  601

Additional paid-in capital 1,181,679  1,111,274

Accumulated deficit (799,190) (801,496)

Accumulated other comprehensive loss (382) (51)

Treasury stock, at cost, 1,355,169 shares as of both January 31, 2026 and 2025 (45,520) (45,520)

Total Stockholders’ Equity 337,207  264,808

Total Liabilities and Stockholders’ Equity $ 663,790  $ 388,415

Phreesia, Inc.

Consolidated Statements of Operations

(Unaudited)

(in thousands, except share and per share data)

Three months ended

January 31, Fiscal year ended

January 31,

2026 2025 2026 2025

Revenue:

Subscription and related services $ 55,924  $ 51,793  $ 219,461  $ 196,510

Payment solutions(1)

35,720  24,676  121,459  101,740

Network solutions 35,423  33,212  139,671  121,563

Total revenues 127,067  109,681  480,591  419,813

Expenses:

Cost of revenue (excluding depreciation and amortization) 18,992  16,507  71,365  66,227

Payment solutions expense(1)

21,398  17,059  82,758  68,707

Sales and marketing 24,656  28,863  100,243  121,129

Research and development 30,925  29,626  121,481  117,364

General and administrative 26,965  18,415  79,903  76,597

Depreciation 3,508  3,172  12,972  14,183

Amortization 6,180  3,651  18,481  13,703

Total expenses 132,624  117,293  487,203  477,910

Operating loss (5,557) (7,612) (6,612) (58,097)

Other income, net 1,273  2,217  2,953  1,956

Loss on extinguishment of debt (501) —  (501) —

Interest expense

(5,807) (586) (6,953) (2,347)

Interest income

269  605  2,173  2,677

Total other (expense) income, net (4,766) 2,236  (2,328) 2,286

Loss before income tax expense (10,323) (5,376) (8,940) (55,811)

Income tax benefit (expense) 11,618  (1,014) 11,246  (2,716)

Net income (loss) $ 1,295  $ (6,390) $ 2,306  $ (58,527)

Net income (loss) per share attributable to common stockholders:

Basic $ 0.02  $ (0.11) $ 0.04  $ (1.02)

Diluted $ 0.02  $ (0.11) $ 0.04  $ (1.02)

Weighted-average common shares outstanding:

Basic 60,403,906  58,277,812  59,737,915  57,589,687

Diluted 61,496,901  58,277,812  61,494,878  57,589,687

(1) The revenue line previously labeled “Payment processing fees” has been relabeled “Payment solutions” to reflect the expanded scope of our payments offerings following the AccessOne Acquisition, which closed on November 12, 2025. “Payment solutions” includes all revenue previously presented as “Payment processing fees” and all revenue from the operations acquired in the AccessOne Acquisition. Additionally, “Payment processing expense” has been relabeled “Payment solutions expense” and includes all expenses previously presented as “Payment processing expense” and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts.

Phreesia, Inc.

Consolidated Statements of Comprehensive Income (Loss)

(Unaudited)

(in thousands)

Three months ended January 31, Fiscal year ended

January 31,

2026 2025 2026 2025

Net income (loss) $ 1,295  $ (6,390) $ 2,306  $ (58,527)

Other comprehensive loss:

Net change in unrealized gains (losses) on cash flow hedges 92  —  (133) —

Change in foreign currency translation adjustments (114) (46) (198) (51)

Other comprehensive loss (22) (46) (331) (51)

Comprehensive income (loss) $ 1,273  $ (6,436) $ 1,975  $ (58,578)

Phreesia, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

Three months ended

January 31, Fiscal year ended

January 31,

2026 2025 2026 2025

Operating activities:

Net income (loss) $ 1,295  $ (6,390) $ 2,306  $ (58,527)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

Depreciation and amortization 9,688  6,823  31,453  27,886

Stock-based compensation expense 18,038  17,162  67,452  66,975

Amortization of deferred financing costs and debt discount 2,792  62  2,977  236

Loss on extinguishment of debt 501  —  501  —

Non-cash gain on settlement —  (2,345) —  (2,345)

Cost of Phreesia hardware purchased by customers 194  625  1,022  1,873

Deferred contract acquisition costs amortization 107  109  570  1,815

Non-cash operating lease expense 257  179  914  747

Deferred taxes (11,830) 38  (13,271) 214

Unrealized gains and losses for fair value option

(1,020) —  (1,020) —

Changes in operating assets and liabilities:

Accounts receivable (8,632) (2,254) (23,397) (8,812)

Collections of principal on receivables originally held for sale to securitization

13,691  —  13,691  —

Accrued Interest Receivable (446) —  (446) —

Prepaid expenses and other assets 3,475  (5,713) (1,393) (1,427)

Deferred contract acquisition costs 17  (280) (334) (1,045)

Accounts payable 3,629  (8,432) 5,261  (3,234)

Accrued expenses and other liabilities 8,526  6,384  2,894  182

Payment of due to provider for receivables originally held for sale to securitization

(17,588) —  (17,588) —

Lease liabilities (375) (202) (1,107) (824)

Deferred revenue 11,343  10,490  8,329  8,667

Net cash provided by operating activities 33,662  16,256  78,814  32,381

Investing activities:

Collections of cardholder receivables held for investment and deferred purchase price 15,709  —  15,709  —

Acquisitions, net of cash acquired (153,191) —  (153,191) —

Capitalized internal-use software (2,578) (4,268) (13,296) (15,380)

Purchases of property and equipment (2,559) (2,790) (11,101) (8,709)

Net cash used in investing activities (142,619) (7,058) (161,879) (24,089)

Financing activities:

Proceeds from issuance of common stock upon exercise of stock options 374  429  1,454  1,012

Proceeds from employee stock purchase plan 396  475  2,371  2,918

Finance lease payments (1,156) (2,641) (6,825) (7,811)

Principal payments on financing agreements (346) (311) (1,330) (1,199)

Debt issuance costs and loan facility fee payments (3,134) —  (3,190) (152)

Financing payments of acquisition-related liabilities —  (4,581) —  (6,254)

Proceeds from debt instruments 110,000  —  110,000  —

Principal payments on debt instruments (20,000) —  (20,000) —

Payments due to provider for unfunded receivables

(9,629) —  (9,629) —

Net cash provided by (used in) financing activities 76,505  (6,629) 72,851  (11,486)

Effect of exchange rate changes on cash, cash equivalents and restricted cash (89) (89) (176) (106)

Net (decrease) increase in cash, cash equivalents and restricted cash (32,541) 2,480  (10,390) (3,300)

Cash and cash equivalents—beginning of period 106,371  81,740  84,220  87,520

Cash, cash equivalents and restricted cash—end of period $ 73,830  $ 84,220  $ 73,830  $ 84,220

Supplemental information of non-cash investing and financing information:

Non-cash activity related to credit card receivables and deferred purchase price

$ 17,585  $ —  $ 17,585  $ —

Right of use assets acquired in exchange for operating lease liabilities $ —  $ —  $ —  $ 1,958

Property and equipment acquisitions through finance leases $ —  $ —  $ —  $ 13,709

Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities $ 1,975  $ 1,787  $ 1,975  $ 1,787

Capitalized stock-based compensation $ 322  $ 356  $ 1,286  $ 1,362

Issuance of stock to settle liabilities for stock-based compensation $ 990  $ 1,213  $ 12,724  $ 11,892

Cash paid for:

Interest $ 721  $ 735  $ 1,614  $ 2,194

Income taxes $ 249  $ 509  $ 1,897  $ 3,068

Non-GAAP Financial Measures

This press release and statements made during the above-referenced webcast may include certain non-GAAP financial measures as defined by SEC rules.

Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net income or loss before interest expense, interest income, income tax (benefit) expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other income, net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs.

The calculation of Adjusted EBITDA was updated beginning in the three months ended October 31, 2025 to include an adjustment for acquisition-related costs, which consist primarily of legal, advisory and other professional fees and integration costs related to acquisitions. Management believes adjusting for these acquisition-related costs provides investors with a more consistent period-to-period comparison of our core operating performance and trends. For periods prior to the three months ended October 31, 2025, the calculation of Adjusted EBITDA did not adjust for acquisition-related costs, and prior periods have not been retroactively adjusted.

We have provided below a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure. We have also presented Adjusted EBITDA in this press release and our Annual Report on Form 10-K to be filed after this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other income, net and income tax (benefit) expense, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss).

Our use of Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

•Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;

•Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; (4) loss on extinguishment of debt; (5) interest expense; (6) interest income; (7) other income, net; or (8) certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs; and

•Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net income (loss) and our GAAP financial results.

The following table presents a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, for each of the periods indicated:

Phreesia, Inc.

Adjusted EBITDA

(Unaudited)

Three months ended

January 31, Fiscal year ended

January 31,

(in thousands) 2026 2025 2026 2025

Net income (loss) $ 1,295  $ (6,390) $ 2,306  $ (58,527)

Interest expense 5,807  586  6,953  2,347

Interest income (269) (605) (2,173) (2,677)

Income tax (benefit) expense (11,618) 1,014  (11,246) 2,716

Depreciation and amortization 9,688  6,823  31,453  27,886

Stock-based compensation expense 18,038  17,162  67,452  66,975

Loss on extinguishment of debt 501  —  501  —

Other income, net (1,273) (2,217) (2,953) (1,956)

Other items affecting comparability(1)

7,250  —  9,223  —

Adjusted EBITDA $ 29,419  $ 16,373  $ 101,516  $ 36,764

(1) For the three months and year ended January 31, 2026, consisted of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition.

We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment.

Additionally, free cash flow is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic investments, partnerships and acquisitions and strengthening our financial position.

The following table presents a reconciliation of free cash flow from net cash provided by operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated:

Phreesia, Inc.

Free cash flow

(Unaudited)

Three months ended

January 31, Fiscal year ended

January 31,

(in thousands) 2026 2025 2026 2025

Net cash provided by operating activities $ 33,662  $ 16,256  $ 78,814  $ 32,381

Less:

Capitalized internal-use software (2,578) (4,268) (13,296) (15,380)

Purchases of property and equipment (2,559) (2,790) (11,101) (8,709)

Free cash flow $ 28,525  $ 9,198  $ 54,417  $ 8,292

Phreesia, Inc.

Supplementary Information

(Unaudited)

Three months ended

January 31, Fiscal year ended

January 31,

(in thousands) 2026 2025 2026 2025

GAAP operating expenses

General and administrative $ 26,965  $ 18,415  $ 79,903  $ 76,597

Sales and marketing 24,656  28,863  100,243  121,129

Research and development 30,925  29,626  121,481  117,364

Cost of revenue (excluding depreciation and amortization) 18,992  16,507  71,365  66,227

$ 101,538  $ 93,411  $ 372,992  $ 381,317

Stock compensation included in GAAP operating expenses

General and administrative $ 7,144  $ 6,301  $ 26,337  $ 24,835

Sales and marketing 5,447  5,456  20,170  21,956

Research and development 4,483  4,213  17,014  15,262

Cost of revenue (excluding depreciation and amortization) 964  1,192  3,931  4,922

$ 18,038  $ 17,162  $ 67,452  $ 66,975

Acquisition-related costs included in GAAP operating expenses

General and administrative $ 7,250  $ —  $ 9,223  $ —

Phreesia, Inc.

Key Metrics

(Unaudited)

Three months ended

January 31, Fiscal year ended

January 31,

2026 2025 2026 2025

Average number of healthcare services clients ("AHSCs") 4,658  4,341  4,514  4,203

Total revenue per AHSC $ 27,279  $ 25,266  $ 106,467  $ 99,884

The definitions of our key metrics are presented below.

•AHSCs. We define AHSCs as the average number of clients that generate subscription and related services or payment solutions revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single healthcare services client. We believe growth in AHSCs is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our solutions to healthcare services organizations that are not yet clients. We believe growth in AHSCs provides useful information to investors as an important indicator of expected revenue growth. In addition, growth in AHSCs informs our management of the areas of our business that will require further investment to support expected future AHSC growth. For example, as AHSCs increase, we may need to add to our customer support team and invest to maintain effectiveness and performance of our solutions for our healthcare services clients and their patients.

•Total revenue per AHSC. We define total revenue per AHSC as total revenue in a given period divided by the number of AHSCs during that same period. Our healthcare services clients directly generate subscription and related services and payment solutions revenue. Additionally, our relationships with healthcare services clients who subscribe to our solutions give us the opportunity to engage with life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations who deliver direct communication to patients through our solutions. As a result, we believe that our ability to increase total revenue per AHSC provides useful information to investors as an indicator of the long-term value of our solutions.

Additional Information

(Unaudited)

Three months ended

January 31, Fiscal year ended

January 31,

2026 2025 2026 2025

Patient payment volume (in millions) $ 1,128  $ 1,080  $ 4,873  $ 4,420

Payment facilitator volume percentage 84  % 82  % 83  % 81  %

The information above reflects our payment processing operations and does not reflect the operations acquired in the AccessOne Acquisition. As of January 31, 2026, AccessOne had a managed portfolio of cardholder receivables of approximately $419 million. For the fourth quarter of fiscal 2026, Access One’s business generated revenues equal to approximately 2.3% of the portfolio.

•Patient payment volume. We believe that patient payment volume is an indicator of both the underlying health of our healthcare services clients’ businesses and the continuing shift of healthcare costs to patients. We measure patient payment volume as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors.

•Payment facilitator volume percentage. We define payment facilitator volume percentage as the volume of credit and debit card patient payments that we process as a payment facilitator as a percentage of total patient payment volume. Payment facilitator volume is a major driver of our payment processing fees revenue. Our payment facilitator volume percentage could decline slightly over time should we increase our penetration of enterprise customers that are less likely to use Phreesia as a payment facilitator.

EX-99.2

EX-99.2

Filename: phr-ex992q4fy26stakehold.htm · Sequence: 3

phr-ex992q4fy26stakehold

Quarterly Stakeholder Letter FOURTH QUARTER | FISCAL YEAR 2026

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 1 Dear Phreesia stakeholders, As we reflect on our fiscal year 2026, we made many important decisions that we believe will set us up for success over the next several years. We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal year 2026. Phreesia’s platform enables more than 1 in 6 patient visits in the U.S. to improve access, affordability and health outcomes. In fiscal year 2026, we extended our reach in the payment and network solutions areas, increasing our addressable market and overall value proposition to existing and new clients. As our business continues to evolve and diversify, we want to ensure that we continue to be surrounded by high-caliber independent directors who complement our existing Board composition. To that end, we were pleased to announce the appointment of Jon Kessler to our Board of Directors, effective April 6, 2026. Jon is a seasoned public company CEO and director who will bring his experience with two companies that, like Phreesia, operate at the intersection of the consumer, financial and healthcare industries. Jon’s knowledge and background make him a strong addition to our Board as we work to drive value for shareholders. Our team continues to be critical to our success. I'm proud to recognize Tiffany McGee, Assistant General Counsel, Commercial Contracts, who was included in The Software Report's 2025 list of the Top Women Leaders in Software, an honor based on demonstrated leadership capabilities and contributions to the software industry. This is the eighth consecutive year that a Phreesia leader has been named to this list. We were also named one of Becker’s 2026 Top Places to Work in Healthcare, a list honoring hospitals, health systems and healthcare companies that are setting the standard for what it means to be an exceptional workplace. Our experienced team entered the new fiscal year with a strong financial profile and several key initiatives including positioning AccessOne for growth, a successful launch of our healthcare provider (HCP) marketing offerings and infusing AI into the Phreesia operating model. We look forward to updating you on our progress in fiscal 2027. MARCH 30, 2026 1 Adjusted EBITDA is a non-GAAP measure. We calculate Adjusted EBITDA as net (loss) income before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. See “Non-GAAP Financial Measures” for more information and a reconciliation of Adjusted EBITDA to the closest GAAP measure. 2 Free cash flow is a non-GAAP measure. We calculate free cash flow as net cash (used in) provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. See the "Non-GAAP Financial Measures" section for a reconciliation of free cash flow to the closest GAAP measure. Chaim Indig Chief Executive Officer and Co-Founder

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 2 Fiscal 2026 Fourth Quarter Highlights3 Revenue Total revenue was up 16% year-over-year to $127.1 million in the fourth fiscal quarter. Year-over-year growth was led by payment solutions4 at 45% (which was significantly boosted by the addition of AccessOne revenue in the quarter), followed by subscription and related services at 8% and network solutions at 7%5. Subscription and related services revenue for the fourth quarter of fiscal 2026 grew 8% compared to the fourth quarter of the prior fiscal year. As we have noted in recent quarters, we expect subscription growth to be slower than payment solutions and network solutions growth, reflecting a deliberate move on our part to moderate subscription pricing to optimize client retention and adoption and to optimize downstream revenue from payment solutions and network solutions. Payment solutions revenue, which includes our legacy payment processing revenue and the new financing fees revenue associated with AccessOne, increased 45% compared to the fourth quarter of the prior fiscal year, consisting of 39% from AccessOne and 6% from legacy Phreesia solutions. Payment processing volume was slightly lower than our expectation, mostly attributable to severe weather across the country in late January 2026. Network solutions revenue increased 7% in the fourth quarter of fiscal 2026 compared to the fourth quarter of the prior fiscal year. As we discussed on our fiscal third quarter 2026 earnings call in early December, we had less visibility into spending commitments from certain pharmaceutical manufacturers, which we reflected in our revenue outlook for network solutions for the remainder of fiscal year 2026. See “Business and Financial Outlook” section for additional developments and our anticipated impact on fiscal year 2027. 3 The fiscal year and fiscal quarter that ended January 31, 2026 should be considered “unaudited.” 4 During the fourth quarter of the fiscal year ended January 31, 2026, the revenue line previously labeled “Payment processing fees” has been relabeled “Payment solutions” to reflect the expanded scope of our payments offerings following the acquisition (the “AccessOne Acquisition”) of AccessOne Parent Holdings, Inc. and its subsidiaries (collectively, “AccessOne”), which closed on November 12, 2025. “Payment solutions” includes all revenue previously presented as “Payment processing fees” and all revenue from the operations acquired in the AccessOne Acquisition. Additionally, “Payment processing expense” has been relabeled “Payment solutions expense” and includes all expenses previously presented as “Payment processing expense” and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts. 5 References to network solutions, subscription and related services, payment solutions and total revenue throughout this letter refer to revenue categories in our consolidated statements of operations: network solutions, subscription and related services, payment solutions, and total revenue, respectively.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 3 Patient Payment Statistics Our payment facilitator volume percentage has remained relatively consistent over time, coming in at 84% in the fourth quarter of fiscal 2026, down 1% on a sequential basis and up 2% year- over-year. As of January 31, 2026, AccessOne had a managed portfolio of cardholder receivables of approximately $419 million. For the fourth quarter of fiscal 2026, the AccessOne business generated revenues equal to approximately 2.3% of the portfolio⁶. Quarterly Revenue1 ($M, Q1 FY2025 - Q4 FY20262) 1 Revenue totals may not sum due to rounding. 2 Fiscal year ended January 31. Subscription and Related Services Payment SolutionsNetwork Solutions Q3 FY26 $55 $37 $27 $120 $47 $27 $27 $49 $28 $25 $49 $33 $25 $52 $33 $25 $54 $32 $30 $101 $102 $107 $110 $116 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 $54 $35 $28 $117 Q4 FY26 $56 $35 $36 $127 6 The AccessOne Acquisition was completed on November 12, 2025. Revenue contributions reflect only the period from November 12, 2025 through January 31, 2026. Though we do not believe these developments are signaling a structural shift in demand for Phreesia's solutions, there is now more variability in our internal network solutions revenue forecasting, particularly in the second half of each fiscal year.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 4 Healthcare Services Clients Average Healthcare Services Clients In the fourth quarter of fiscal 2026, we supported 4,658 Average Healthcare Services Clients (AHSCs)7, an increase of 138 AHSCs (or 3%) over the third quarter of fiscal 2026 and an increase of 317 AHSCs (or 7%) year-over-year. Of the 138 AHSCs added in the fourth quarter, 80 AHSCs were contributed through the acquisition of AccessOne. Total Revenue Per AHSC In the fourth quarter of fiscal 2026, total revenue per AHSC8 was $27,279, up 8% year-over-year. Revenue growth is driven by two factors: 1) the growth of our network of healthcare services clients; and 2) our ability to drive more value for our existing clients through products across our platform that are designed to address three foundational challenges in healthcare delivery: access to care, affordability of care and health outcomes. We generate three types of revenue from these products: subscription and related services, payment solutions and network solutions revenue. We believe that having multiple methods of monetizing our network is a key factor behind our historical revenue growth. 7 We define AHSCs as the average number of clients that generate subscription and related services or payment solutions revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single healthcare services client. 8 We define total revenue per AHSC as total revenue in a given period divided by the number of AHSCs during that same period. Total Revenue Per AHSC ($000’s) AHSCs 6 4,658 $27.3 Q4 FY2 4,520 $26.6 Q3 FY26 4,065 4,169 4,237 4,341 4,411 $24.9 $24.5 $25.2 $25.3 $26.3 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 $26.2 4,467 Total Revenue Per AHSC¹ (Q1 FY2025 - Q4 FY20262) 1 Calculations for each period are presented as total revenue for that period divided by the number of AHSCs during the same period. Total revenue per AHSC may not add up to annual results due to rounding. 2 Fiscal year ended January 31.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 5 Phreesia Solutions Our broad capabilities bring value to patients, providers and Life Sciences companies in unique ways. Streamline Registration In-office and telehealth workflows ID and insurance card capture Demographics Document / eSignature management Bedside / informed consent Analytics and data reporting Patient satisfaction surveys Online reviews Simplify Patient Access Secure two-way messaging Appointment reminders Auto-fill cancellations Auto-rebook no-shows / bumps VoiceAI answering service (scheduling, payments, refill prescriptions) After-hours call triaging (VoiceAI) Drive Growth MediFind provider directory and appointment booking Automated referral outreach Appointment self-scheduling Online appointment requests Marketing campaigns for premium services Broadcast messaging Improve Outcomes Patient Activation Measure (PAM®) Patient recall for delayed or missed care Patient-reported outcomes and clinical screening tools Social determinants of health screenings Targeted outreach for preventive care Automated vaccine workflows Accelerate Cash Flow Funded A/R programs Payment reminders Pre-visit / time-of-service  payment capture Card-on-file Simplify the Payments Journey Automated E&B verification Transparent statements Flexible payment plans Digital and mobile payments (incl. Apple Pay and GooglePay) Access Access Access Affordability Affordability Patient Outcome

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 6 Access VoiceAI During the second fiscal quarter, we introduced our AI-powered call-answering solution, VoiceAI. Phreesia VoiceAI is a virtual health assistant that addresses a core operational issue in healthcare delivery: answering patient phone calls reliably and efficiently. VoiceAI is designed to support patient access by identifying what the caller needs through natural conversation. It handles routine call types related to billing and payments, appointment management, prescription refill requests, after-hours clinical questions and more by collecting relevant patient details and completing or triaging the request in a consistent way. This reduces the amount of time staff spend on repetitive call handling and helps patients reach the appropriate next step without waiting on hold. Today, VoiceAI acts as a digital front door: For scheduling, the agent can text patients a link to any online scheduling tool, or take a message. We also recently launched the ability for VoiceAI to cancel and rebook appointments directly in scheduling systems. For billing, the agent can take a payment using card on file, if the organization processes payments through Phreesia, or send a link to pay online through any payment platform. For prescription refills, the agent can capture details like medication, dosage and preferred pharmacy, and route that information to staff to action or follow up on. Healthcare IT News recently published a success story on Phreesia VoiceAI, illustrating its real-world operational and financial impact at Evergreen Family Medicine, a growing primary care practice serving 50,000+ patients in rural Oregon. The article underscores how VoiceAI helped Evergreen Family Medicine overcome phone system bottlenecks that were creating long hold times, inefficient call handling and escalating costs. Because of its integration with the practice’s EHR and intelligent routing capabilities, the system handled 100,000 calls in its first two months, virtually eliminated hold times and significantly reduced manual work for staff. Results in the first two months also included: $650,000 in cost savings, primarily by eliminating dependence on expensive third-party call services and inefficiencies. 20,000 staff hours reclaimed, allowing team members to reallocate time toward direct patient support. These results highlight not only the operational return on investment our platform delivers, but also the financial impact it can unlock for provider organizations. We are excited about opportunities to continue integrating AI into our solutions to further enhance the value of the Phreesia platform.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 7 Affordability & Cash Flow AccessOne Our investment thesis on AccessOne has been reinforced over the past several months since we closed the acquisition, and we are encouraged by the stability and execution we’ve seen. AccessOne continues to operate at enterprise scale, serving 80 AHSCs and delivering strong collection performance. Since closing, our focus has been on client continuity, operational alignment and integration planning, and the business is performing in line with our expectations. Our strategy includes augmenting our current access to capital in order to offer AccessOne’s solutions to a greater portion of our addressable market of healthcare providers. We look forward to updating you on our progress in bringing this solution to our base clients by unlocking capital on their balance sheets to help support their growth. GoodRx Partnership During fiscal year 2026, Phreesia also saw impactful results from an innovative partnership with GoodRx, the leading platform for medication savings. Aimed at educating patients about medication adherence at the point of care and streamlining access to cost-saving resources, the partnership combines GoodRx’s deep expertise in improving medication affordability with the scale of Phreesia’s network and its ability to reach patients at key moments in their healthcare journey. Patients may see relevant messages about medication cost savings before checking in on the Phreesia platform for their doctor’s appointment, as well as after their visit. Over a 10-month period ending November 30, 2025, our analysis shows Phreesia delivered more than 19 million engagements, resulting in over 1.6 million requests for GoodRx coupon savings. Those engagements resulted in more than 476,000 claims using GoodRx coupons and estimated patient savings of $9.5 to $12 million. Poor medication adherence has profound impacts, including worsening symptoms, hospitalizations, increased mortality and higher healthcare costs. According to a GoodRx survey, more than a quarter of U.S. patients who left a prescription unfilled said it was due to cost. Only 37% of Americans report talking about medication affordability with their healthcare professionals, according to the survey, underscoring the value of providing cost-savings information to patients before their visit. More than one in three patients who saw GoodRx messages on the Phreesia platform said they were very likely to talk to their healthcare provider or a pharmacist about GoodRx after viewing the content, and almost half said they were very likely to use GoodRx, according to a Phreesia analysis.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 8 Phreesia Network Solutions’ most well-known media offering, PatientConnect, is a highly effective tool trusted by the top 20 pharmaceutical manufacturers. Drawing on the strengths of PatientConnect, ProviderConnect also leverages the pre-appointment window of time, centers on patient-level relevance, keeps privacy at the center, and is powered by real-world care signals instead of inference and engagement data alone. Measurable Impact: Prescription Initiation and Adherence A recent third-party validated, holdout-controlled study demonstrates the real-world impact of Phreesia’s Post-Script Engagement solution. As shared in previous letters, our Post-Script Engagement product helps bridge the critical gap between prescriptions written and filled by delivering important patient reminders that support medication adherence. By comparing patients who received post- prescription engagement to a matched control group, the analysis showed true incremental behavior change across both therapy initiation and ongoing adherence. "As a clinician, keeping up with the pace of medical advances—and applying new information in real time during increasingly short appointments—is incredibly challenging," said Dr. Alicia Cowley, Medical Director at Phreesia Network Solutions. "ProviderConnect solves this problem by giving HCPs the right resources before the visit, helping them recognize less common presentations, consider new or updated treatment options for the patient in front of them, and proactively address side effects and cost so patients can make informed decisions and stay engaged in their care.” Health Outcomes ProviderConnect In early March, we announced the launch of ProviderConnect, a first-of-its-kind offering for healthcare provider (HCP) marketers. Drawing on over two decades of experience of pioneering digital tools for direct-to-consumer health marketers, ProviderConnect enables life sciences brands and others across the healthcare space to smartly engage relevant HCPs in a low-waste, high-impact way. ProviderConnect reimagines how HCP outreach can happen. Instead of broad-reach awareness blasts, this new tool lets teams reach the right clinicians at the right time based on cases they are likely to see in upcoming practice.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 9 The results included: 25% lift in first fills compared to the control 8% lift in refills compared to the control 105 incremental first fills generated 89 incremental refills generated Nearly $1 million in total value driven, evenly split between: ~$511,000 from new starts ~$481,000 from retention These findings show that targeted engagement immediately after prescribing can influence both initial conversion and continued adherence. By extending activation beyond the patient-provider encounter, Post-Script Engagement translates clinical intent into measurable treatment starts and sustained therapy continuation, demonstrating the tangible outcomes delivered through our network solutions platform. ‘What is Lp(a) Testing?’ Campaign with Novartis Phreesia and Novartis Pharmaceuticals Corporation developed a ‘What Is Lp(a) Testing?’ PatientConnect campaign to address a significant awareness gap around high lipoprotein(a) (Lp(a)), an inherited cardiovascular disease risk factor that can increase the likelihood of cardiovascular events, including heart attack and stroke, and which was recognized by only 3% of high-risk patients prior to the initiative. Unbranded, evidence-based education was delivered during digital check-in to clinically defined high- risk patients, positioning the information immediately before provider visits when blood testing for high Lp(a) could be ordered if necessary. Results demonstrated strong engagement and meaningful intent lift against Phreesia benchmarks: Doctor Discussion Guides were requested at 4x cardiovascular benchmark rates For patients with a history of premature cardiovascular events, these guides were requested at 5.4x benchmark rates 40% of patients with premature cardiovascular events indicated they were very likely to speak with their physician about high Lp(a) (50% lift compared to the control) 37% of patients with premature cardiovascular events said they were likely to discuss Lp(a) testing (50% lift compared to the control) For patients with a family history of cardiovascular events, 26% were very likely to ask for an Lp(a) test (40% lift compared to the control) These outcomes show that delivering unbranded point-of-care education, right before the exam, moved many high-risk patients from near-zero Lp(a) awareness to Phreesia benchmark-beating discussion guide uptake and strong stated intent to initiate testing conversations with their providers.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 10 Revenue Growth and Operating Leverage As depicted in the following charts, revenue growth has been complemented by significant operating leverage for several quarters leading up to the fourth quarter of fiscal 2026. Our expense ratios have generally improved throughout the last two fiscal years, as revenue growth outpaces expense growth. See the “Non-GAAP Financial Measures” section of this letter for a reconciliation of net (loss) income to Adjusted EBITDA. Total Revenue ($M, Q1 FY2025 - Q4 FY20261) $127 Q4 FY26 $101 $102 $107 $110 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 $116 Q2 FY26 $117 $120 Q3 FY26 1 Fiscal year ended January 31.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 11 1 Amounts may not add up to annual results due to rounding. 2 Fiscal year ended January 31. 3 Adjusted EBITDA is a non-GAAP measure. We calculate Adjusted EBITDA as net (loss) income before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. See “Non-GAAP Financial Measures” for more information and a reconciliation of Adjusted EBITDA to the closest GAAP measure. Net (Loss) Income and Adjusted EBITDA¹ ($M, Q1 FY2025 - Q4 FY20262) Net (Loss) Income Adjusted EBITDA Q2 FY26Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 $(20) $(18) $(14) $(6) $4 $7 $10 $16 $21 $(4) $ $1 $4 22 $29 Q3 FY26 $1 $29 Q4 FY26 Cost of Revenue Cost of revenue (excluding depreciation and amortization) increased $2.5 million to $19.0 million for the three months ended January 31, 2026, as compared to $16.5 million for the three months ended January 31, 2025. The increase resulted primarily from a $2.3 million increase in other third-party costs and a $0.1 million increase in labor costs. Stock compensation incurred related to cost of revenue was $1.0 million and $1.2 million for the three months ended January 31, 2026 and 2025, respectively.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 12 Payment Solutions Expense9 Payment solutions expense increased $4.3 million to $21.4 million for the three months ended January  31, 2026, as compared to $17.1 million for the three months ended January 31, 2025. The increase resulted primarily from the increase in payment processing fees revenue and patient payments processed through our solutions, each driven by an increase in patient visits over the prior year, as well as additional payment solutions expense recognized for AccessOne. It is also worth noting that payment solutions expense as a percentage of payment solutions revenue declined because AccessOne's financing fees revenue carries lower direct costs than interchange-based payment processing fees revenue. Our payment solutions expense as a percentage of payment solutions revenue was 60% in the fourth quarter of fiscal 2026, compared to 72% and 69% in the third quarter of fiscal 2026 and the fourth quarter of fiscal 2025, respectively. The decrease in payment solutions expense as a percentage of payment solutions revenue was primarily driven by the addition of AccessOne, which typically produces higher margins. Sales & Marketing Sales and marketing expense decreased $4.2 million to $24.7 million for the three months ended January 31, 2026, as compared to $28.9 million for the three months ended January 31, 2025. The decrease resulted primarily from a $4.0 million decrease in labor costs and a $0.2 million decrease in other third-party sales and marketing costs. Stock compensation incurred related to sales and marketing expense was $5.4 million and $5.5 million for the three months ended January 31, 2026 and 2025, respectively. Research & Development Research and development expense increased $1.3 million to $30.9 million for the three months ended January 31, 2026, as compared to $29.6 million for the three months ended January 31, 2025. The increase resulted primarily from a $0.6 million increase in software costs, a $0.4 million increase in labor costs and a $0.3 million increase in other third-party research and development costs. Stock compensation incurred related to research and development expense was $4.5 million and $4.2 million for the three months ended January 31, 2026 and 2025, respectively. General & Administrative General and administrative expense increased $8.6 million to $27.0 million for the three months ended January 31, 2026, as compared to $18.4 million for the three months ended January 31, 2025. The increase primarily resulted from a $7.3 million increase in acquisition-related and restructuring costs, a $1.2 million increase in labor costs, partially offset by a $0.1 million increase in other third-party costs. Stock compensation incurred related to general and administrative expense was $7.1 million and $6.3 million for the three months ended January 31, 2026 and 2025, respectively. 9 During the fourth quarter of the fiscal year ended January 31, 2026, “Payment processing expense” has been relabeled “Payment solutions expense” and includes all expenses previously presented as “Payment processing expense” and direct costs of revenue related to the operations acquired in the AccessOne Acquisition. Prior period amounts have not been reclassified, as the Company did not own the acquired operations in prior periods and the change in presentation did not affect any previously reported amounts.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 13 Operating Expense Trends ($M, Q1 FY2025 - Q4 FY20261) 1 Fiscal year ended January 31. 2 Subscription & network solutions cost as a percentage of revenue equals cost of revenue (excluding depreciation and amortization), divided by the sum of subscription and related services revenues and network solutions revenues, each per our unaudited consolidated statements of operations for the periods presented. 3 Payment solutions expense as a percentage of revenue equals payment solutions expense divided by payment solutions revenues, each per our unaudited consolidated statements of operations for the periods presented. Q3 FY26 Q3 FY26 Q3 FY26 Q3 FY26 Q3 FY26 20% 20% $24 24% $29 15% $17 72% 19% Sales & Marketing $ / % Total revenue 22% $26 32% $32 Research & Development $ / % Total revenue 27% $32 29% $29 General & Administrative $ / % Total revenue 14% $16 19% $19 Payment Solutions Expense3 % Revenue 72%68% Subscription & Network Solutions Cost of Revenue % Revenue 21% 21% 66% 30% $30 29% $30 19% $19 22% 68% 28% $30 27% $29 18% $20 19% 69% 26% $29 27% $30 17% $18 Q2 FY26Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 20% 22% $25 25% $29 16% $19 71% Q4 FY26 Q4 FY26 Q4 FY26 Q4 FY26 Q4 FY26 21% 19% $25 24% $31 21% $27 60%

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 14 Balance Sheet and Liquidity As of January 31, 2026 and January 31, 2025, we had cash, cash equivalents and restricted cash of $73.8 million and $84.2 million, respectively. Cash, cash equivalents and restricted cash consist of money market funds and cash on deposit at various financial institutions. AccessOne Acquisition On November 12, 2025 (the “Closing Date”), we acquired AccessOne for consideration transferred of approximately $164 million, including post-closing adjustments. The purchase price was funded with a combination of cash and the net proceeds from a new, 364-day $110 million secured term loan (the “Bridge Loan”) entered into on the Closing Date. Also on the Closing Date, we entered into an amendment (the “Credit Facility Amendment”) to our senior ABL facility with Capital One, National Association (as amended, the “Existing Capital One Credit Facility”). The Credit Facility Amendment amended certain terms of the Existing Capital One Credit Facility to permit the acquisition of AccessOne and to accommodate the existence of the Bridge Loan. During the fourth quarter of fiscal 2026, we repaid $20 million of the outstanding principal balance of the Bridge Loan. As of January 31, 2026, a balance of $90 million was outstanding under the Bridge Loan. For more information regarding the AccessOne Acquisition, the Bridge Loan and the Credit Facility Amendment, please see our Current Reports on Form 8-K and Form 8-K/A filed with the SEC on September 4, 2025, November 12, 2025 and January 28, 2026. New Capital One Credit Facility and Refinancing On March 13, 2026, subsequent to the end of the fiscal year, we completed a refinancing pursuant to which we repaid all outstanding indebtedness and obligations under the Bridge Loan with $92 million of borrowings from a new 5-year $275 million senior secured revolving credit facility (the “New Capital One Credit Facility”) maturing on March 13, 2031. The New Capital One Credit Facility also replaces the Existing Capital One Credit Facility, which had no outstanding borrowings and was terminated on the same date. The unused borrowing capacity on the New Capital One Credit Facility is available to the Company for working capital, capital expenditures, permitted acquisitions and general corporate purposes. As the January 31, 2026 outstanding principal balance of the Bridge Loan was refinanced onto long- term debt prior to the issuance of this letter and accompanying earnings release, we classified the outstanding principal balance of the Bridge Loan as long-term debt in the accompanying consolidated balance sheet as of January 31, 2026. With the refinancing of our debt complete, we intend to prioritize allocation of capital to areas that we believe can enhance long-term shareholder value. These priorities may include the paydown of our long- term debt, investment to support revenue growth acceleration and share repurchases, as appropriate. For more information regarding the New Capital One Credit Facility and the and the termination of the Bridge Loan and the Existing Capital One Credit Facility, please see our Current Report on Form 8-K filed with the SEC on March 16, 2026.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 15 Cash Flow In the fourth quarter of fiscal 2026, net cash provided by operating activities10 was $33.7 million, an improvement of $17.4 million year-over-year, as compared to $16.3 million in the fourth quarter of fiscal 2025. In the fourth quarter of fiscal 2026, we generated free cash flow11 of $28.5 million, an improvement of $19.3 million year-over-year, as compared to $9.2 million in the fourth quarter of fiscal 2025. In the fourth quarter of fiscal 2026, the quarter-over-quarter improvements in operating cash flow and free cash flow were driven primarily by changes in working capital and operating cash flows provided by AccessOne. The quarter-over-quarter improvement in operating cash flow and free cash flow are expected to fluctuate, driven by the timing of invoicing and payments. These variations are reflected in changes in working capital, alongside the timing of capital expenditures. The following charts summarize how growth in our net cash (used in) provided by operating activities, or operating cash flow, has driven growth in free cash flow. See the “Non-GAAP Financial Measures” section of this letter for a reconciliation of net cash (used in) provided by operating activities to free cash flow. 10 References to net cash provided by operating activities, free cash flow and net cash (used in) provided by operating activities throughout this letter are related to our cash flow categories in our consolidated statements of cash flows and free cash flow reconciliation within Part II - Item 8 of our Annual Report on Form 10-K. 11 Free cash flow is a non-GAAP measure. We calculate free cash flow as net cash (used in) provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. See the “Non-GAAP Financial Measures” section for a reconciliation of free cash flow to the closest GAAP measure. Operating Cash Flow ($M, Q1 FY2025 - Q4 FY20261) 1 Fiscal year ended January 31. Net cash (used in) provided by operating activities Q4 FY26 $15.5$14.8 $11.1 $5.8 $16.3 Q2 FY26Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 $(0.7) $14.9 Q3 FY26 $33.7

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 16 Q3 FY26 $8.8 $3.7 $1.6 $9.2 Q2 FY26Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 $(6.2) $7.5 $9.6 Q4 FY26 $28.5 Free Cash Flow ($M, Q1 FY2025 - Q4 FY20261) 1 Fiscal year ended January 31. The following table summarizes our operating, investing and financing cash flows: $M Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Net cash (used in) provided by operating activities $(0.7) $11.1 $5.8 $16.3 $14.9 $14.8 $15.5 $33.7 Net cash used in investing activities $(5.4) $(7.4) $(4.2) $(7.1) $(7.4) $(5.2) $(6.7) $(142.6) Net cash (used in) provided by financing activities $(1.8) $(1.4) $(1.7) $(6.6) $(0.8) $(2.1) $(0.7) $76.5

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 17 Business and Financial Outlook We are lowering our revenue outlook for fiscal 2027. We expect revenue to be in the range of $510 million to $520 million from a previous range of $545 million to $559 million. As we discussed on our last earnings call in December 2025, we are experiencing shorter visibility into spending commitments by certain pharmaceutical manufacturers. As we enter fiscal 2027, network solutions clients are committing lower spend levels for the second half of fiscal 2027 than we had anticipated last December. Certain clients are committing fewer dollars due to brand-specific dynamics including the impact of regulatory policies. Though we do not believe these developments are signaling a structural shift in demand for Phreesia's solutions, there is now more variability in our internal network solutions revenue forecasting, particularly in the second half of each fiscal year. Our visibility into revenue across the other parts of our business is generally consistent with our views in December 2025. The revenue range provided for fiscal 2027 assumes approximately $37 million of contribution from AccessOne and no additional revenue from potential future acquisitions completed between now and January 31, 2027. We are maintaining our Adjusted EBITDA outlook for fiscal 2027. We expect Adjusted EBITDA to be in the range of $125 million to $135 million. Our Adjusted EBITDA outlook implies that we will absorb much of the reduction in our revenue outlook. In addition to our continued confidence in the operating leverage embedded in our model, we have more recently identified significant opportunities to reduce our reliance on manual processes across Phreesia through the adoption of artificial intelligence. Initially, we expect to see efficiencies in our utilization of outsourced resources. We continue to expect improvement in operating leverage across the Company through a focus on efficiency. We are maintaining our expectation for AHSC growth in the mid-single-digit percentage range, and we are lowering our outlook for total revenue per AHSC to the low-single-digit percentage range for fiscal 2027, compared to low double-digit growth previously. About Phreesia Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 180 million patient visits in 2025—1 in 6 visits across the U.S. This scale allows Phreesia to make meaningful impact across the healthcare ecosystem. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives operational efficiency and improves healthcare outcomes. To learn more, visit phreesia.com. Media contact: Nicole Gist nicole.gist@phreesia.com Investor contact: Balaji Gandhi investors@phreesia.com

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 18 Non-GAAP Financial Measures This stakeholder letter and statements made during the webcast referenced below may include certain non-GAAP financial measures as defined by SEC rules. Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net income or loss before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs. The calculation of Adjusted EBITDA was updated beginning in the three months ended October 31, 2025 to include an adjustment for acquisition-related costs, which consist primarily of legal, advisory and other professional fees and integration costs related to acquisitions. Management believes adjusting for these acquisition-related costs provides investors with a more consistent period-to-period comparison of our core operating performance and trends. For periods prior to the three months ended October 31, 2025, the calculation of Adjusted EBITDA did not adjust for acquisition-related costs, and prior periods have not been retroactively adjusted. We have provided below a reconciliation of Adjusted EBITDA to net (loss) income, the most directly comparable GAAP financial measure. We have also presented Adjusted EBITDA in the press release accompanying this letter and in our Annual Report on Form 10-K to be filed after this letter because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors. We have not reconciled our Adjusted EBITDA outlook to GAAP net (loss) income because we do not provide an outlook for GAAP net (loss) income due to the uncertainty and potential variability of other expense (income), net, income tax expense (benefit), which are reconciling items between Adjusted EBITDA and GAAP net (loss) income. Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net (loss) income. Our use of Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 19 • Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; • Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; (4) loss on extinguishment of debt; (5) interest expense; (6) interest income; (7) other income, net; or (8) certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring-related costs; and • Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure. Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP- based financial performance measures, including various cash flow metrics, net (loss) income and our GAAP financial results. $M Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Net (loss) income $(19.7) $(18.0) $(14.4) $(6.4) $(3.9) $0.7 $4.3 $1.3 Interest expense 0.6 0.6 0.6 0.6 0.4 0.4 0.3 5.8 Interest income (0.8) (0.7) (0.6) (0.6) (0.2) (1.0) (0.7) (0.3) Income tax expense (benefit) 0.5 0.8 0.4 1.0 0.7 (1.2) 0.9 (11.6) Depreciation and amortization 6.7 7.3 7.1 6.8 6.9 7.4 7.5 9.7 Stock-based compensation expense 16.8 16.4 16.5 17.2 17.2 16.2 16.0 18.0 Loss on extinguishment of debt – – – – – – – 0.5 Other expense (income), net – 0.1 0.1 (2.2) (0.3) (0.3) (1.0) (1.3) Other items affecting comparability1 – – – – – – 2.0 7.3 Adjusted EBITDA2,3 $4.1 $6.5 $9.8 $16.4 $20.8 $22.1 $29.1 $29.4 1 For the three months ended October 31, 2025 and January 31, 2026, consisted of legal, advisory and other professional fees and integration costs related to the AccessOne Acquisition. 2 We calculate Adjusted EBITDA as net (loss) income before interest expense, interest income, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, other expense (income), net and certain other items that are not considered to reflect our operating activities and performance within the ordinary course of business, such as acquisition- and restructuring- related costs. The calculation of Adjusted EBITDA was updated beginning in Q3 of fiscal 2026 to include an adjustment for acquisition-related costs. Prior periods have not been retroactively adjusted. Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. 3 May not foot due to rounding.

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 20 We calculate free cash flow as net cash (used in) provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. Additionally, free cash flow is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investments, partnerships and acquisitions, and strengthening our financial position. The following table presents a reconciliation of free cash flow to net cash (used in) provided by operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated: $M Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Net cash (used in) provided by operating activities $(0.7) $11.1 $5.8 $16.3 $14.9 $14.8 $15.5 $33.7 Less: Capitalized internal-use software (4.6) (3.0) (3.6) (4.3) (3.9) (3.4) (3.4) (2.6) Purchases of property and equipment (0.9) (4.4) (0.6) (2.8) (3.5) (1.8) (3.3) (2.6) Free Cash Flow1,2 $(6.2) $3.7 $1.6 $9.2 $7.5 $9.6 $8.8 $28.5 1 We calculate free cash flow as net cash (used in) provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. Additionally, free cash flow is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investments, partnerships and acquisitions, and strengthening our financial position. 2 May not foot due to rounding. Forward-Looking Statements This stakeholder letter includes express or implied statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, Adjusted EBITDA and cash flows; our expectations regarding demand for our solutions and visibility into future revenue; our expectations regarding improvement in operating

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 21 leverage across the Company through a focus on efficiency; the expected results of the AccessOne Acquisition discussed herein, including anticipated additional revenue, Adjusted EBITDA and AHSCs; our estimated addressable market; our outlook for fiscal 2027, including with respect to revenue, Adjusted EBITDA and our expectations on AHSCs, total revenue per AHSC, and our plans to achieve our revenue and Adjusted EBITDA targets in fiscal 2027; our ability to continue generating positive net income and free cash flow; our expectations regarding growth in subscription and related services revenue over the long term; our ability to finance our plans to achieve our fiscal 2027 outlook with our current cash balance along with cash generated in the normal course of business; our business strategy and operating plans; our capital allocation priorities; industry trends and predictions; our anticipated growth and operating leverage; the factors that drive our revenue growth; our expectations regarding new solutions and solutions under development and the use of artificial intelligence in our solutions; our growth strategies for the AccessOne business, our ability to offer the AccessOne solution to additional clients and our plans to augment our access to capital; and our expectations regarding the growth of our network of clients and partners. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: the ability to integrate operations or realize any operational or corporate synergies and other benefits from the AccessOne Acquisition; our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the competitive environment in which we operate; our ability to comply with the covenants in the New Capital One Credit Facility; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; difficulties in integrating our acquisitions and investments; artificial intelligence that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data, increasing our regulatory and compliance burden and increasing competition; and other general market, political, economic and business conditions (including from the U.S. federal government, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this letter are also subject to other risks and uncertainties, including those listed or described in our filings with the SEC, including in our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 that

QUARTERLY STAKEHOLDER LETTER | FOURTH QUARTER 2026 | 22 will be filed with the SEC after this letter. The forward-looking statements in this letter speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this letter to reflect events or circumstances after the date of this letter or to reflect new information or the occurrence of unanticipated events, except as required by law. This letter also includes statistical data, estimates and forecasts that are based on industry publications or other publicly available information, as well as other information based on our internal sources. This information may be based on many assumptions and limitations, and you are cautioned not to give undue weight to such information. We have not independently verified the accuracy or completeness of the information contained in these industry publications and other publicly available information. Conference Call Information We will hold a conference call on Monday, March 30, 2026 at 5:00 PM ET to review our fiscal 2026 fourth quarter and fiscal 2026 financial results. To participate in our live conference call and webcast, please dial (800) 715-9871 (or (646) 307-1963 for international participants) using conference code number 7404611 or visit the “Events & Presentations” section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold001.jpg · Sequence: 7

Binary file (125235 bytes)

Download phr-ex992q4fy26stakehold001.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold002.jpg · Sequence: 8

Binary file (250691 bytes)

Download phr-ex992q4fy26stakehold002.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold003.jpg · Sequence: 9

Binary file (238143 bytes)

Download phr-ex992q4fy26stakehold003.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold004.jpg · Sequence: 10

Binary file (144902 bytes)

Download phr-ex992q4fy26stakehold004.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold005.jpg · Sequence: 11

Binary file (179857 bytes)

Download phr-ex992q4fy26stakehold005.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold006.jpg · Sequence: 12

Binary file (156151 bytes)

Download phr-ex992q4fy26stakehold006.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold007.jpg · Sequence: 13

Binary file (212895 bytes)

Download phr-ex992q4fy26stakehold007.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold008.jpg · Sequence: 14

Binary file (212978 bytes)

Download phr-ex992q4fy26stakehold008.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold009.jpg · Sequence: 15

Binary file (214229 bytes)

Download phr-ex992q4fy26stakehold009.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold010.jpg · Sequence: 16

Binary file (212712 bytes)

Download phr-ex992q4fy26stakehold010.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold011.jpg · Sequence: 17

Binary file (100066 bytes)

Download phr-ex992q4fy26stakehold011.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold012.jpg · Sequence: 18

Binary file (137103 bytes)

Download phr-ex992q4fy26stakehold012.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold013.jpg · Sequence: 19

Binary file (253714 bytes)

Download phr-ex992q4fy26stakehold013.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold014.jpg · Sequence: 20

Binary file (144099 bytes)

Download phr-ex992q4fy26stakehold014.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold015.jpg · Sequence: 21

Binary file (255376 bytes)

Download phr-ex992q4fy26stakehold015.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold016.jpg · Sequence: 22

Binary file (172337 bytes)

Download phr-ex992q4fy26stakehold016.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold017.jpg · Sequence: 23

Binary file (81114 bytes)

Download phr-ex992q4fy26stakehold017.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold018.jpg · Sequence: 24

Binary file (255519 bytes)

Download phr-ex992q4fy26stakehold018.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold019.jpg · Sequence: 25

Binary file (271465 bytes)

Download phr-ex992q4fy26stakehold019.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold020.jpg · Sequence: 26

Binary file (208553 bytes)

Download phr-ex992q4fy26stakehold020.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold021.jpg · Sequence: 27

Binary file (205133 bytes)

Download phr-ex992q4fy26stakehold021.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold022.jpg · Sequence: 28

Binary file (332120 bytes)

Download phr-ex992q4fy26stakehold022.jpg

GRAPHIC

GRAPHIC

Filename: phr-ex992q4fy26stakehold023.jpg · Sequence: 29

Binary file (141079 bytes)

Download phr-ex992q4fy26stakehold023.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 31

v3.26.1

Document and Entity Information Document

Mar. 30, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Mar. 30, 2026

Entity Registrant Name

Phreesia, Inc.

Amendment Flag

false

Entity Central Index Key

0001412408

Entity Incorporation, State or Country Code

DE

Entity File Number

001-38977

Entity Tax Identification Number

20-2275479

Entity Address, Address Line One

1521 Concord Pike

Entity Address, Address Line Two

Suite 301 PMB 221

Entity Address, City or Town

Wilmington

Entity Address, State or Province

DE

Entity Address, Postal Zip Code

19803

City Area Code

888

Local Phone Number

654-7473

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

PHR

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration